tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

This study is testing whether giving immunotherapy (a drug called tislelizumab) to cancer patients who have finished their standard curative treatment but still show traces of cancer in their blood (called molecular residual disease, or MRD) can prevent the cancer from coming back. Even after successful surgery and chemotherapy, tiny amounts of cancer DNA can sometimes be detected in the bloodstream — a sign that the cancer may return. This study targets that window to intervene early. **You may be eligible if:** - You are 18 or older - You have completed standard curative treatment for stage II–III non-small cell lung cancer, stage II–III colorectal cancer, stage I–III pancreatic cancer, or grade 3 limb/trunk soft tissue sarcoma - Testing shows molecular residual disease (ctDNA positive) in your blood after completing treatment - You have no visible cancer on imaging - Your physical health (ECOG 0–1) and organ function meet requirements - You have not received prior immunotherapy **You may NOT be eligible if:** - You have visible cancer on imaging - You have previously received immunotherapy (anti-PD-1 or anti-PD-L1) - Your organ function is insufficient - Your blood tests for residual cancer were not done in the required timeframe Talk to your doctor to see if this trial is right for you.